<DOC>
	<DOCNO>NCT00105040</DOCNO>
	<brief_summary>A 12-week Evaluation Period use characterize potential cognitive neuropsychological effect LEV ( 20 - 60 mg/kg/day ) , adjunctive treatment child 4 - 16 year old , inclusive , refractory partial onset seizure compare adjunctive treatment placebo .</brief_summary>
	<brief_title>A 19-week Cognition Study Levetiracetam Children With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Pediatric subject ( 4 16 year old ) diagnose refractory partial onset seizure minimum six month prior Visit 1 experience least two partial onset seizure four week prior Visit 1 enrol Subjects stable regimen one maximum two antiepileptic drug ( AEDs ) least 2 week prior Visit 1 Subject must Intelligence Quotient ( IQ ) assess Visit 1 least 70 Subject parent/guardian fluent English Subject must previous treatment levetiracetam unless , opinion investigator , subject 's previous treatment inadequate dose duration provide accurate assessment therapy , effect levetiracetam confound concomitant medication Subject receive benzodiazepine routine chronic basic unable discontinue use four week prior Visit 1 Subject seizure close together accurately count Subject current psychiatric disorder mild moderate attention deficit , behavior , learn disorder</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Partial onset seizure</keyword>
	<keyword>epilepsy</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>Keppra</keyword>
	<keyword>cognition</keyword>
	<keyword>behavior</keyword>
	<keyword>pediatry</keyword>
</DOC>